EU External Trade - Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale, Other

Extra-EU sourcing of Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale, Other is highly concentrated. 🇺🇸 United States captures 56.8% of imports (€5.1B), followed by 🇨🇭 Switzerland (21.7%). With an HHI of 3774, this Concentrated market exposes the EU to supply dependency risks.

The main extra-EU export markets for Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale, Other are 🇺🇸 United States, 🇷🇺 Russia, 🇯🇵 Japan. 🇺🇸 United States absorbs 47.4% of European exports (€4.7B).

Within the EU, the leading importers of Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale, Other are 🇧🇪 Belgium, 🇩🇪 Germany, 🇪🇸 Spain. 🇧🇪 Belgium accounts for 24.5% of EU imports.

In 2025, imports were falling sharply (-19.5%) and exports declining (-6.9%) compared to the previous year.